Skip to content


Hereditary Cancer in Clinical Practice

Open Access

Sebaceous neoplasms in Lynch syndrome

  • Monica Dandapani1Email author,
  • Anu Chittenden1,
  • Aaron J Stunkel1,
  • Margery Rosenblatt1,
  • Sapna Syngal1 and
  • Elena M Stoffel1
Hereditary Cancer in Clinical Practice20119(Suppl 1):P7

Published: 10 March 2011


Lynch SyndromeTorre VariantSebaceous CarcinomaPREMM ModelSebaceous Adenoma


Sebaceous neoplasms of the skin (SN) are described in the Muir Torre variant of Lynch syndrome (LS). Guidelines recommend evaluating individuals diagnosed with sebaceous adenomas or sebaceous carcinomas for LS with immunohistochemistry (IHC) for mismatch repair (MMR) proteins and/or microsatellite instability analysis (MSI). The assumption has been that SNs with defective MMR are related to LS.


To describe outcomes of genetic testing for LS among individuals with SN.


24 individuals with a personal history of SN underwent a genetic evaluation for Lynch syndrome (LS) at Dana-Farber Cancer Institute. 10 had family histories which met Amsterdam criteria, 8 had a personal history of another LS-associated malignancy, 23 had family history of one or more LS-associated cancers, and 1 had no other personal or family history of cancer.

11/24 (46%) probands had pathogenic MMR gene mutations (2 MLH1 and 9 MSH2) and each of these either met Amsterdam criteria or had a personal history of another LS-related cancer.

Of 13 probands without identifiable MMR mutations, 6 had SNs with normal IHC and 7 had abnormal IHC (3 absent MSH2 and MSH6, 2 absent MLH1 and PMS2, 1 absent MLH1 only and 1 absent MSH2 only). One of the probands whose SN showed absence of MSH2 and MSH6 had a family history which met Amsterdam criteria (PREMM score=33%) and the rest had PREMM model scores <5%.


Although prior reports suggest that MSI/IHC can be useful in screening patients with SNs for LS, we found many of these tumors demonstrate features of abnormal MMR even when family history is not suggestive of LS and genetic testing did not reveal MMR mutation. Further study is needed to determine whether other somatic mechanisms may produce the MMR deficient phenotypes seen in many SNs.

Authors’ Affiliations

Dana-Farber Cancer Institute, Boston, USA


© Dandapani et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.